About Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. It offers active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, over-the-counter (OTC) products, innovative products, and custom pharmaceutical services, with focus areas including gastrointestinal, cardiovascular, and oncology therapies . The company serves patients in 83 countries, underpinned by research and development in Telangana and Andhra Pradesh (India) and Cambridge (UK), and manufacturing in Telangana, Andhra Pradesh, Himachal Pradesh (India), Cuernavaca‑Cuautla (Mexico), and Mirfield (UK) . Major markets include the USA, India, Russia & CIS, China, Brazil, and Europe; its shares trade on the BSE, NSE, NSE IFSC (India) and NYSE (U.S.). 

As per the consolidated notes, the group had 55 subsidiaries (including step‑down subsidiaries) during the year; it also reports joint ventures and associates separately. 

Dr. Reddy’s Laboratories Limited’s Business Segments

• By segment (FY2025, IFRS): Global Generics 88.9%; Pharmaceutical Services and Active Ingredients (PSAI) 10.4%; Others 0.7%.
• Within Global Generics (share of total revenue): North America 44.6%; Europe 11.0%; India 16.5%; Emerging Markets 16.8%.

Dr. Reddy’s Laboratories Limited Key Management

• K Satish Reddy – Chairman
• G V Prasad – Co‑Chairman and Managing Director
• Erez Israeli – Chief Executive Officer
• M V Narasimham – Chief Financial Officer (w.e.f. August 1, 2024)
• K Randhir Singh – Company Secretary and Compliance Officer
• Deepak Sapra – Chief Executive Officer, API and Services
• M V Ramana – Chief Executive Officer, Branded Markets (India and Emerging Markets)
• Milan Kalawadia – Chief Executive Officer, North America
• Patrick Aghanian – Chief Executive Officer, Europe Generics

Latest Updates on Dr. Reddy’s Laboratories Limited

• Strategic expansion: Acquisition of Nicotinell and other leading Nicotine Replacement Therapy (NRT) brands, strengthening the consumer healthcare franchise in Europe and beyond.

• Partnerships: Entered a nutrition venture with Nestlé in India; received U.S. rights for Cyclophosphamide from Ingenus; launched Galvus (anti‑diabetes) in Russia.

• Corporate action: Completed a 1:5 forward stock split effective October 28, 2024 .
• Portfolio rationalisation: Dr. Reddy’s Laboratories Louisiana LLC was divested on March 21, 2025; the Venezuela subsidiary was dissolved on June 5, 2024.

• Scale and reach: The company reported launches across key markets during FY2025 and highlighted a global footprint serving patients in 83 countries, supported by 26,944 employees (as disclosed in the corporate overview).